it matters who you ask.
We’re transforming cancer care by delivering tomorrow’s answers today.
NEO | Pan Tracer LBxTM
Our new liquid biopsy solution for pan-cancer
therapy selection.
NeoGenomics provides unmatched partnership to support pharmaceutical companies, accelerating drug development and clinical trials through a network of College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. Partner with us for reliable, end-to-end support in bringing life-changing therapies to patients faster.
Our technology and test offerings are constantly evolving to offer state-of-the-art testing capabilities that align to the latest evidence and guidelines.
NeoGenomics provides unparalleled client support to help providers diagnose and choose the right therapy selection testing to address gaps in cancer care.
With over a decade of experience, NeoGenomics has contributed to a wealth of research, uncovering insights to advance breakthroughs in cancer diagnostics.
